CTI opens new offices to support anticipated demand for regenerative medicine expertise

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Ankabala)
(Image: Getty/Ankabala)

Related tags: CTI Clinical Trial and Consulting Services, Regenerative medicine, Immune-oncology, Rare disease

The CRO is adding two new offices in the US to support what has been significant growth over the past several years from pharma and biotech customers working in rare diseases and immune-oncology.

CTI Clinical Trial and Consulting Services (CTI), contract research organization (CRO) headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific.

The company today announced the opening of new offices in Dallas, TX and San Diego, CA.

“We chose Dallas and San Diego because of the talent pool and other resources we see in those communities and the opportunities they present for both CTI and our pharmaceutical and biotechnology sponsors,”​ said Timothy Schroeder, CTI founder and CEO.

Schroeder said the specific job functions in the new offices will vary and include different clinical operations positions, with the services to be the same as the company’s other offices.

Several employees have already been hired at each office and more expected to be added in the coming months. “The rate of growth will be driven by the quality of the candidates,” ​explained Schroeder.

“In the past several years, we have seen significant growth from the pharmaceutical/biotechnology industry in the areas of cell and gene therapies, especially in rare diseases and immune-oncology,” ​he added.

Schroeder said, “As we’ve been working in the field since before it had a name, we anticipate demand for our regenerative medicine expertise to continue to increase.”

In line with this, the company in April​ doubled its footprint in Raleigh, NC and moved its West Coast office in San Francisco to a larger space. 

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Related suppliers

Follow us

Products

View more

Webinars